

IN THE CLAIMS

Cancel Claims 1-13 without prejudice and insert therefor new Claims 21-39 as follows:

B¹
~~21.~~ (New) A method for the treatment or prevention of a disorder selected from: single episodic major depressive disorder, recurrent major depressive disorder, dysthymic disorder, bipolar disorder and cyclothymic disorder in a human in need thereof which comprises administering to the human an effective amount of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.0, 15.3, 16.6, 17.0, 17.6, 19.4, 20.0, 21.9, 23.6, 23.8, and 24.8° (2 theta) which is substantially free of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)-phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.6, 16.7, 17.1, 17.2, 18.0, 20.1, 20.6, 21.1, 22.8, 23.9, and 24.8° (2 theta).

~~22.~~ (New) The method of Claim ~~21~~¹ wherein the disorder is single episodic major depressive disorder.

~~23.~~ (New) The method of Claim ~~21~~³ wherein the disorder is recurrent major depressive disorder.

~~24.~~ (New) The method of Claim ~~21~~⁴ wherein the disorder is dysthymic disorder.

~~25.~~ (New) The method of Claim ~~21~~⁵ wherein the disorder is bipolar disorder.

~~26.~~ (New) The method of Claim ~~21~~⁶ wherein the disorder is bipolar I disorder.

B

⁷
~~27~~. (New) The method of Claim ~~21~~⁷ wherein the disorder is bipolar II disorder.

⁸
~~28~~. (New) The method of Claim ~~21~~¹ wherein the disorder is cyclothymic disorder.

⁹
~~29~~. (New) A method for the treatment or prevention of a disorder selected from: panic disorder with agoraphobia, panic disorder without agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, obsessive-compulsive disorder, stress disorder and generalised anxiety disorder in a human in need thereof which comprises administering to the human an effective amount of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)-methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.0, 15.3, 16.6, 17.0, 17.6, 19.4, 20.0, 21.9, 23.6, 23.8, and 24.8° (2 theta) which is substantially free of a polymorphic form of the compound 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine characterized by an X-ray powder diffraction pattern with key reflections at approximately: 12.6, 16.7, 17.1, 17.2, 18.0, 20.1, 20.6, 21.1, 22.8, 23.9, and 24.8° (2 theta).

¹⁰
~~30~~. (New) The method of Claim ~~29~~⁹ wherein the disorder is panic disorder with agoraphobia.

¹¹
~~31~~. (New) The method of Claim ~~29~~⁹ wherein the disorder is panic disorder without agoraphobia.

¹²
~~32~~. (New) The method of Claim ~~29~~⁹ wherein the disorder is agoraphobia without history of panic disorder.

¹³
~~33~~. (New) The method of Claim ~~29~~⁹ wherein the disorder is specific phobia.

¹⁴
~~34~~ (New) The method of Claim ⁹~~29~~ wherein the disorder is social phobia.

¹⁵
~~35~~ (New) The method of Claim ⁹~~29~~ wherein the disorder is obsessive-compulsive disorder.

¹⁶
~~36~~ (New) The method of Claim ⁹~~29~~ wherein the disorder is stress disorder.

¹⁷
~~37~~ (New) The method of Claim ¹⁶~~36~~ wherein the stress disorder is post-traumatic stress disorder.

¹⁸
~~38~~ (New) The method of Claim ¹⁶~~36~~ wherein the stress disorder is acute stress disorder.

¹⁹
~~39~~ (New) The method of Claim ⁹~~29~~ wherein the disorder is generalised anxiety disorder.
